Psoriatic Arthritis (PsA) Treatment Market Comprehensive Study 2018 | Pfizer Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A.

Leading Manufacturers of Biologics Hold More Than 56% Market Share

The psoriatic arthritis (PsA) treatment market is dominated by key manufacturers competing on the basis of different prices, and have different approved drugs and undergoing clinical trials for psoriatic arthritis (PsA) treatment market. Leading manufacturers in the psoriatic arthritis (PsA) treatment market are engaged in the research and development of biologics and biosimilars, along with expansion activities through partnerships, acquisitions, and collaborations.

AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, and other key companies in biologics hold more than 56% revenue share in the global psoriatic arthritis (PsA) treatment market. These companies are continuously making efforts to expand their product portfolios in the psoriatic arthritis (PsA) treatment market. Through collaborations, acquisitions, and partnerships, companies dealing in psoriatic arthritis (PsA) treatment are focusing on improving their regional footprints and developing new biologics and TNF inhibitors.

Development of New Oral Treatment

Oral treatment has emerged with a sophisticated approach for the treatment of psoriatic arthritis (PsA) treatment. The Food and Drug Administration (FDA) approved apremilast (Otezla, Celgene Corporation), the first selective inhibitor of phosphodiesterase 4 (PDE4) indicated for adults with active PsA, in March 2014. Otezla for psoriatic arthritis (PsA) treatment with or without concomitant DMARDs, compared with other oral treatment along with or without DMARDs, shows great improvement in the signs and symptoms of psoriatic arthritis (PsA). Otezla also offers patients and physicians a new psoriatic arthritis (PsA) treatment option, with the potential to help psoriatic arthritis (PsA) patients, which further increases the adoption of oral treatment, and significantly drives the market for psoriatic arthritis (PsA) treatment.

Get Sample Copy of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2718

Flourishing Combination Treatment and Dual Inhibitors

TNF inhibitors and interlukin-17 inhibitors such as secukinumab seem to be a promising combination therapy for psoriatic arthritis (PsA) treatment. Recent pre-clinical investigations have shown that, the combination is significantly capable of reducing joint pathology in murine experimental arthritis. Hence, a future combination of TNF inhibitors with an anti-IL-17 antibody seems plausible, which is expected to significantly drive the psoriatic arthritis (PsA) treatment market.

Moreover, a new era of bi-specific antibodies is expected to push the market growth of psoriatic arthritis (PsA) treatment over the forecast period. For instance, Covagen AG is investigating a bi-specific antibody - COVA322 targeting TNF/IL-17 in a phase Ib/Iia clinical trial. AbbVie Inc. is investigating an ABT 122-an antibody with dual specificity binding both, TNF and IL-17, in a phase II clinical trial.

Biomarkers to Facilitate Diagnosis and Treatment

A number of potential biomarkers are under investigation for psoriatic arthritis (PsA) treatment, which include soluble markers (e.g., C-reactive protein, matrix metalloproteases), cell populations (e.g., osteoclast precursors, relevant T cell subsets), and tissue resident markers in the joints (e.g., RANKL) or skin.

Recent advances in the targeted biological therapy have allowed patients to experience remission from PsA and psoriasis. In addition, biomarkers can be used to monitor the development of adverse reactions to specific treatment modalities, which significantly fuels the growth of psoriatic arthritis (PsA) treatment market.

Competitive Landscape

This section of the report features the profiles of key players operating in the psoriatic arthritis (PsA) treatment market based on their differential strategies, market shares, product offerings, marketing approach, and company dashboard. Examples of some of the key players featured in this report include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Eli Lilly & Co, Novartis AG, Celgene Corporation, and AstraZeneca PLC, among others.

Key manufacturers in the psoriatic arthritis (PsA) treatment market are focusing on developing new biologics drugs and biosimilars to enhance effectivity and patient compliance.

Definition

Psoriatic arthritis (PsA) (PsA) is a chronic condition that combines the sore, swollen joints of arthritis along with psoriasis. Psoriasis causes scaly patches, which are itchy on the skin and scalp. Psoriatic arthritis (PsA) is related to the immune system, like psoriasis. The immune response causes inflammation, which triggers joint pain, swelling, and stiffness. Inflammation affects the entire body and leads to permanent tissue and joint damage if not treated earlier and aggressively.Psoriatic arthritis (PsA) treatment includes NSAIDS, DMARDs, and biologics.

Request Customized Copy of Report @ https://www.futuremarketinsights.com/customization-available/rep-gb-2718

About the Report

The company conducted a research study on the psoriatic arthritis (PsA) treatment market for the forecast period 2018 to 2028. The report offers a comprehensive evaluation of the business opportunities prevailing in the psoriatic arthritis (PsA) treatment market, along with insights on the current trends and analysis on clinical trials.

Additional Questions Answered

Some of the additional questions addressed in this report on the psoriatic arthritis (PsA) treatment market-

What is the revenue potential of the psoriatic arthritis (PsA) treatment market across the regions of North America and Europe?

Who are the key competitors and what are their portfolios in the psoriatic arthritis (PsA) treatment market?

What are major challenges influencing the growth of the psoriatic arthritis (PsA) treatment market?

How is intervention from regulatory authority shaping the growth of the psoriatic arthritis (PsA) treatment market?

Research Methodology

The psoriatic arthritis (PsA) treatment market has been estimated based on the prevalence and incidence rate approach. The market was first calculated based on the prevalence and incidence rate for calculating the base population in different region/countries. Other qualitative factors analyzed during volume estimation include different treatment options and diagnosis rates, treatment rate and percentage adoption of currently available treatment options in various stages of the disease, to obtain target population. This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions, and viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals, and resourceful databases). The research study also includes top trends and macro as well as micro economic factors shaping the psoriatic arthritis (PsA) treatment market. With this approach, the report anticipates the industry attractiveness of every major segment in the psoriatic arthritis (PsA) treatment over the forecast period.

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Web: https://www.futuremarketinsights.com/

This release was published on openPR.